Posts tagged “Aurora”
Metabolon, whose proprietary technology has applications in medical diagnostics as well as food and nutrition, is getting a financial boost from two new investors as well as six existing ones in its new round of funding.
Triangle-based Aurora Funds is among the participants in the latest round of funding for Regado, which is developing DNA-based blood treatments.
Police and narcotics officials can use Centice devices to identify controlled prescription drugs and illegal narcotics. Centice this year released a mobile narcotics identification system that law enforcement can use in the field.
The Durham-based drug development firm lands a new investor as well as more backing from Intersouth and Aurora Funds. The deal follows Argos' recent decision to terminate plans to go public.
Nanotech companies are clamoring for financing at a time when investor purse strings remains tight. Some investors are showing interest in nanotechnology investments, but that interest doesn't mean that they approach these deals with any less caution.
The Durham based venture capital-backed firm estimated an IPO price of between $13 and $15 per share. Some 5.25 million shares will be offered.
Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective regenerative medicine therapies for its pipeline. But a payoff remains in the future and depends on drug trial results.
Regenerative medicine company Cytomedix has acquired the venture-capital backed company in a $16 million stock deal plus millions more in stock options. Aldagen investors include Intersouth and Aurora Funds.
The financing for the Durham-based firm that is backed by The Aurora Funds follows a $2.1 million fundraising nearly a year ago. Six existing investors in the company participated in the latest offering,
The Triangle-based company, which focuses on biomarker technology, secures a new investor. Local venture firm Aurora Funds also is an investor.
The Durham-based biopharmaceutical firm focuses on individualized therapies targeting cancer, HIV and infectious diseases. Its investors include Intersouth Partners and Aurora Funds.
The Durham-based company recently withdrew plans for an $80 million stock offering.
The Morrisville-based company, which reorganized its management in 2009, says the funds will be used to drive growth of existing, new chemical verification and identification products.
The Durham-based startup sometimes touted as the "Google of video" is growing face, developing more technology that's finding increasing demand in the online video archiving space.
The Durham-based life science company cites "market conditions" as the reason for the pullback. It's the second time that the company, which is backed by Triangle venture firms Intersouth and Aurora, has cancelled an IPO.
- Britain's leaving the EU. What should I do with my money?
- No plan for layoffs, store closures as Southern Season restructures
- British brace for economic repercussions of EU exit decision
- Inventor with Duke connection seeks to subdue cellphone addiction
- Markets reel as world absorbs shock of UK vote for Brexit
- Women-led startups flex muscles at healthcare investment showcase
- Tech links: Epic v. Microsoft; Wilmington at Forbes; IBM blockchain; Arista-Cisco patent fight; IBM cloud foundation; GSK malaria vaccine
- Triangle headlines: RTI-Zika research; Quintiles glucose monitoring; Cree's LED plant lights; PatientPay exec; Q2 award